Further Issuance. The Company may from time to time, without the consent of the Holders of the Notes, issue additional Securities (the “Additional Securities”) of this series having the same ranking and the same interest rate, maturity and other terms as the Notes. Any Additional Securities of this series and the Notes will constitute a single series under the Indenture and all references to the Notes shall include the Additional Securities unless the context otherwise requires.
Appears in 8 contracts
Samples: Indenture (Celgene Corp /De/), Indenture (Celgene Corp /De/), Indenture (Celgene Corp /De/)
Further Issuance. The Company may from time to time, without the consent of the Holders of the Notes, issue additional Securities (the “Additional Securities”) of this series Series having the same ranking and the same interest rate, maturity and other terms as the Notes. Any Additional Securities of this series Series and the Notes will constitute a single series Series under the Indenture and all references to the Notes shall include the Additional Securities unless the context otherwise requires.
Appears in 5 contracts
Samples: Third Supplemental Indenture (Biogen Inc.), Second Supplemental Indenture (Biogen Inc.), Senior Note Agreement (Biogen Inc.)
Further Issuance. The Company may from time to time, without the consent of the Holders of the Notes, issue additional Securities (the “Additional Securities”) of this series having the same ranking and the same interest rate, maturity Maturity and other terms as the Notes. Any Additional Securities of this series and the Notes will constitute a single series under the Indenture and all references to the Notes shall include the Additional Securities unless the context otherwise requires.
Appears in 1 contract
Further Issuance. The Company may from time to time, without the consent of the Holders Securityholders of the Notes, issue additional Securities (the “Additional Securities”) of this series having the same ranking and the same interest rate, maturity and other terms as the Notes. Any Additional Securities of this series and the Notes will constitute a single series under the Indenture and all references to the Notes shall include the Additional Securities unless the context otherwise requires.
Appears in 1 contract
Samples: First Supplemental Indenture (Regeneron Pharmaceuticals, Inc.)